The OCMX™ is pleased to announce the listing of Nativis Inc. to its online portal which offers Investors and Advisors the ability to participate in this opportunity.

SEATTLE, WA, March 28, 2018 /24-7PressRelease/ — Nativis has invented a groundbreaking therapeutic device technology that uses ultra-low radio frequency energy (ulRFE®) to interrupt disease mechanisms on the molecular and genetic levels – without chemicals or radiation. Nativis ulRFE is able to replicate the biological activity of a broad range of molecules including proven drugs, siRNA, mRNA, and endogenous compounds like hormones. The resulting therapeutic product profile provides localized delivery of a proven mechanism of action, avoiding systemic toxicity, and allowing for cost-effective combination therapy (multiple targets on one device). The therapeutic benefit is delivered via a simple-to-use investigational device called Nativis Voyager®, pictured below. The controller weighs 6 ounces and the coil can be shaped to deliver the ulRFE® field to the desired areas of the body, avoiding exposure of other organs to maximize safety.

The OCMX™ is pleased to announce the listing of Nativis Inc. to its online portal which offers Investors and Advisors the ability to participate in this opportunity.

The OCMX™ has spent considerable time completing its due diligence on Nativis Inc. and concluded that there is indeed a tremendous opportunity for Investors and Advisors.

The OCMX™ noted that Nativis Inc. exhibits the main components of any solid investment opportunity, namely a solid management team, a great track record, and a number of key competitive advantages.

MANAGEMENT TEAM

Chris E. Rivera – President, Chief Executive Officer and Chairman of the Board |Chris brings more than 30 years of experience in the biotechnology industry. Chris was the Founder and CEO of Hyperion Therapeutics, which was acquired by Horizon Pharma in 2015, the Senior Vice President and head of Commercial Operations at both Tercica, where he led the cross-licensing transaction between Tercica and Ipsen, and Genzyme Therapeutics, where he built and ran Genzyme’s US renal Commercial Operations, he also helped launch Genzyme’s renal division globally. Prior to Genzyme, he helped build Cephalon and Centocor’s initial commercial infrastructures.

Kenneth Ferguson, PhD – Chief Scientific Officer | Ken is Chief Scientific Officer at Nativis. Prior to joining Nativis, Ken was vice president and chief development officer at Omeros Corporation, CEO of VacTX, and spent 16 years at ICOS Corporation in research and development, where he was Product Development Team Leader and later the Chief Scientific Officer and Board member of the Lilly ICOS Joint Venture.

Ken is a graduate of Cornell University and The University of Texas Health Science Center at Dallas. His doctoral research with Dr. Al Gilman focused on signal transduction, specifically the mechanism by which G proteins participate in the action of G protein-coupled receptors. Ken completed post-doctoral studies with Dr. Michael Wigler at Cold Spring Harbor Laboratory with a focus on oncogenes and the cell cycle.

Xavier A. Figueroa, PhD – Director, Pre-clinical Development | Xavier is the principal scientist for Nativis overseeing pre-clinical research and the application of Nativis technology in multiple disease areas. He has more than 20 years of experience in basic and neurological clinical research, including Alzheimer’s research, neuron biology, cancer research, bioengineering and biophysics.

He has advised emerging biotechnology companies, most notably Cytokinetics and ENG3. Xavier has also served on non-profit Scientific Advisory boards for such organizations as the Brain Health and Healing Foundation and published broadly in multiple areas of science and medicine.

Xavier received his doctoral degree in Neurobiology & Behavior from the University of Washington. His doctoral training was followed by two post-doctoral fellowships within the University of Washington’s Department of Bioengineering. He is currently an affiliate assistant professor in the School of Medicine at the University of Washington.

David Matteson, MPH, MEd, MPA – Investor Relations and Education |David is a seasoned business leader and strategist, who has dedicated his career to advancing health innovations, services, and products into the market place. Prior to joining Nativis full time in 2012, he consulted to early- and growth-stage companies in healthcare to develop strategic plans, raise capital, craft public policy campaigns, design and implement marketing and branding programs, manage company growth and change, and foster high-performance teams at both the board and C-suite levels. As an executive coach he has worked with dozens of entrepreneurs to hone their ideas into viable business structures and lead their ventures through the volatile journey to market.

David has a diverse background that spans five academic preparations and numerous executive positions across several industries. This broad base of training and experience provides a unique, integrated, and long-view perspective that is valuable when designing integrated business structures and strategies to move innovation into the market. He has a proven track record of brokering and managing multi-disciplinary teams to tackle complex business opportunities.

Michael Mischke-Reeds, MA – SVP of Business Development | Michael has over 25 years of leadership experience in life sciences companies, having worked as a startup biotech executive and a management consultant, specializing in biotechnology. After studying biology and management science at Stanford University, he co-founded startup companies Fast Track Systems (software to support pharmaceutical clinical development) and Chiron Informatics (disease management software for HIV). His management consulting career started at Strategic Decisions Group (world leader in pharmaceutical asset valuation and portfolio management) and then cofounded Keelin Reeds Partners (biotech-focused consulting firm offering valuation, strategy, and transaction support). Michael is currently Senior Vice President of Business Development for Nativis, where he leads partnering activities as well as strategy and valuation.

Donna Morgan Murray, PhD – Chief Regulatory Officer |Donna is the Chief Regulatory Officer for Nativis. A seasoned healthcare professional, she has more than 30 years of experience in the biotechnology and pharmaceutical industries. She’s authored more than 60 publications and served on several non-profit boards and organizations. Donna holds a PhD from the University of Texas Health Science Center at Houston.

Eric Peterson – Director of Development and Manufacturing |Eric brings more than 20 years of experience in developing, manufacturing and commercializing innovative medical devices in fast growing start-up companies. He serves as the Director of Development and Manufacturing at Nativis, where he is responsible for leading design, development and manufacturing operations with strategic partners while ensuring compliance with FDA and ISO standards.

Steven Pope, MA (Oxon) JD – Corporate Secretary and Sr. VP, General Counsel |Steven is responsible for overseeing the legal affairs of the Company, including contracts, securities, governance, intellectual property, and employment matters. Prior to joining Nativis in 2010, Steven was a Partner at Perkins Coie LLP.

Steven received his J.D. cum laude from Seattle University School of Law where he was a member of the Law Review, his M.A. from the University of Oxford, and his B.A. summa cum laude from Gonzaga University.

Gabriel Vogeli, PhD – Senior Distinguished Scientist | Gabriel, Distinguished Scientist, is the former Director of Molecular Biology for Dendreon Corporation, former Senior Scientist at Upjohn Company/Pharmacia-Upjohn and Senior Staff Fellow at the National Institutes of Health. Gabriel holds a PhD from the University of Zurich, and was a Postdoctoral Fellow at Yale University.

ABOUT THE OCMX™

The OCMX™ is literally changing how companies and investment funds generate exposure in the marketplace and raise funds as we know it. The OCMX™ serves both public and private companies along with investment and mutual funds which need to raise additional funds or gain significant market exposure. It does this by way of connecting the relevant companies, funds, investors, and advisors all in one online transparent portal. The OCMX™ (P2P Financial Inc.) launched in September of 2009 out of Toronto but has since expanded its operations to include Quebec, Alberta, Manitoba, and British Columbia.

The OCMX™ connects investors and advisors directly with companies and investment funds seeking to raise funds or gain broad market exposure. The OCMX™ provides an open venue for innovative growth companies and leading investment funds to generate market awareness, raise funds, or connect with investors and advisors. The OCMX™ provides companies, funds, investors, and advisors instant access to its Online Portal so that they can actively source and connect with their next opportunity, advisor, investor, client, or financing partner.

Contact Us
The OCMX™
TD Canada Trust Tower
161 Bay Street, 45th Floor
Toronto, Ontario, M5J 2S1
Tel: 1-866-209-6862
Email: [email protected]


For the original version of this press release, please visit 24-7PressRelease.com here